Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Chipotle Mexican Grill, Inc. (CMG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Chipotle Mexican Grill, Inc. — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.76 (market cap $5.07B), while Chipotle Mexican Grill, Inc. trades at $32.58 (market cap $40.49B). The key difference: Chipotle Mexican Grill, Inc. is far larger — about 8× ACADIA Pharmaceuticals Inc.'s market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Chipotle Mexican Grill, Inc. nearer its low. Which is the better fit depends on your goals.
| ACAD | CMG | |
|---|---|---|
Market Cap | $5.07B | $40.49B |
Sector | Health | Consumer Cyclical |
52-Week High | $29.41 | $44.04 |
52-Week Low | $20.06 | $28.17 |
Enterprise Value | $4.19B | $45.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.39, up 0.62% on the day, with strong earnings momentum after Q2 2026 results beat expectations. The stock shows bullish technical signals from moving averages, though oscillators suggest potential overbought conditions. Revenue growth has been robust, rising from $517M in 2022 to $1.07B in 2025, with net income turning positive and margins expanding significantly. Recent news highlights FDA Fast Track designation for remlifanserin and raised 2026 revenue guidance.
Outlook remains positive driven by product sales growth and pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Analyst consensus is strongly bullish with a $33.89 price target, indicating ~15% upside. Investment appeal hinges on execution of commercial strategy and successful drug development.
Chipotle Mexican Grill (CMG) trades at $32.25, up 0.34% on the day, amid a bearish technical signal despite recent earnings beats. The stock faces headwinds from a recent salmonella outbreak linked to jalapeños, contributing to a 12.64% weekly drop. Fundamentally, revenue growth remains robust, reaching $11.93B in 2025, with strong profitability metrics including a 49.56% ROE. Analyst consensus is overwhelmingly bullish with a $42.17 price target, though technical indicators show selling pressure with key support at $32.
The outlook for CMG balances strong fundamentals against near-term operational risks. Wall Street's buy ratings (70.15%) reflect confidence in long-term growth, but recent food safety issues and declining net income margins pose immediate challenges. Investors should weigh the company's consistent revenue trajectory against potential volatility from ongoing outbreaks and rising costs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Chipotle Mexican Grill, Inc.
Chipotle Mexican Grill is the largest fast-casual chain restaurant in the United States, with systemwide sales of $7.5 billion in 2021. The Mexican concept is entirely company-owned, with a footprint of more than 3,000 stores, heavily indexed to the United States (though the firm maintains a small presence in Canada, the U.K., France, and Germany). Chipotle sells burritos, burrito bowls, tacos, quesadillas, and beverages, with a selling proposition built around competitive prices, high-quality food sourcing, speed of service, and convenience. The company generates its revenue entirely from restaurant sales and delivery fees.
Read more on CMG →
